CONTENTS

Dedication ......................................................................................................................v
Preface ......................................................................................................................... vii
Contributors...................................................................................................................xi

Part I. Introduction
Chapter 1. Cardiac Safety of Noncardiac Drugs:
  Historical Recollections ............................................................... 3
  Raymond John Lipicky

Part II. Preclinical and Pharmacogenomic
Cardiac Safety Evaluations
Chapter 2. Molecular Physiology of Ion Channels That Control
  Cardiac Repolarization ............................................................... 13
  Jeanne M. Nerbonne and Robert S. Kass
Chapter 3. Cellular, Molecular, and Pharmacologic Mechanisms
  Underlying Drug-Induced Cardiac Arrhythmogenesis .......... 37
  Charles Antzelevitch
Chapter 4. hERG Assay, QT Liability, and Sudden Cardiac Death ................ 67
  Arthur M. Brown
Chapter 5. Pharmacogenomics in Drug Development:
  When and How to Apply ............................................................ 83
  Richard Judson and Arthur J. Moss

Part III. Clinical Methodologies and Technical Aspects of Assessing
Cardiac Safety of Investigational Drugs:
Focus on Cardiac Repolarization
Chapter 6. Assessment of Ventricular Repolarization
  From Body-Surface ECGs in Humans ..................................... 107
  Jean-Philippe Couderc and Wojciech Zareba
Chapter 7. ECG Acquisition and Signal Processing:
  12-Lead ECG Acquisition ........................................................ 131
  Justin L. Mortara
Chapter 8. Digital 12-Lead Holter vs Standard Resting Supine
  Electrocardiogram for the Assessment of Drug-Induced
  QTc Prolongation: Assessment by Different Recording
  and Measurement Methods ...................................................... 147
  Nenad Sarapa
Chapter 9. Holter Monitoring for QT: The RR Bin Method in Depth .......... 167
  Fabio Badilini and Pierre Maison-Blanche
Part IV. Application of Electrocardiology in Clinical Research

Chapter 10. Fundamentals of ECG Interpretation in Clinical Research and Cardiac Safety Assessment ............................................... 189
  Ihor Gussak, Robert Kleiman, and Jeffrey S. Litwin
Chapter 11. Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs .......................................................... 205
  Joel Morganroth
Chapter 12. Use of ECGs in Support of Cardiac Safety in Phase II and III Clinical Trials ................................................................. 223
  Martin P. Bedigian
Chapter 13. Cardiac Arrhythmia Assessment in Phase IV Clinical Studies ... 229
  Gerald A. Faich and Annette Stemhagen
Chapter 14. Statistical Analysis Plans for ECG Data: Controlling the Intrinsic and Extrinsic Variability in QT Data .................. 239
  Alan S. Hollister and Timothy H Montague
Chapter 15. Interpretation of Clinical ECG Data: Understanding the Risk From Non-Antiarrhythmic Drugs ............................................ 259
  Rashmi R. Shah

Part V. Regulatory Considerations

Chapter 16. The FDA’s Digital ECG Initiative and Its Impact on Clinical Trials ...................................................................... 301
  Barry D. Brown
Chapter 17. Quality Control and Quality Assurance for Core ECG Laboratories ................................................................. 329
  Amy M. Annand-Furlong
Chapter 18. ECG Digital Communities and Electronic Reporting of Cardiac Safety Data: New Technologies for Reporting Digital ECG Data in Clinical Research Settings .............. 339
  Scott Grisanti and Robert Brown

Index ........................................................................................................................... 355
Cardiac Safety of Noncardiac Drugs
Practical Guidelines for Clinical Research and Drug Development
Morganroth, J.; Gussak, I. (Eds.)
2005, XII, 362 p., Hardcover
ISBN: 978-1-58829-515-6
A product of Humana Press